Frequently Asked Questions
The market is segmented based on , By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine), Vaccine (MMR, PPSV23, DTaP, Respiratory Syncytial Virus (RSV), Haemophilus Influenzae Type B (Hib)), Disease Type (Tuberculosis, Pertussis, Influenza Virus, Streptococcus Pneumoniae (Pneumonia), Chronic Obstructive Pulmonary Disease (COPD), Diphtheria, Others), Age (Infant, Adolescent, Adult), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.
.
The Global Respiratory Disease Vaccine Market size was valued at USD 23.42 USD Billion in 2024.
The Global Respiratory Disease Vaccine Market is projected to grow at a CAGR of 5.7% during the forecast period of 2025 to 2031.
The major players operating in the market include Bavarian Nordic, Bayer AG, AstraZeneca, Bio Farma, Dynavax Technologies, Emergent BioSolutions , Merck Sharp & Dohme Corp., Pfizer , GlaxoSmithKline plc, Seqirus, Sanofi, Serum Institute of India Pvt. , CSL Limited, Novavax, INOVIO Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation.
